Nazol Advance nasal spray 0.025 mg/dose 150 doses 10 ml
Latin name
Nazol Advance
Release form
Nasal spray.
pharmachologic effect
Vasoconstrictor drug for local use in ENT practice. Oxymetazoline hydrochloride causes vasoconstriction of the mucous membranes of the nose, paranasal sinuses and eustachian tube, which reduces their swelling and leads to easier nasal breathing. Relief of nasal breathing occurs 5-10 minutes after injection into the nasal cavity and lasts up to 12 hours. Menthol, camphor, eucalyptol have a local decongestant, anti-inflammatory and antiseptic effect, thin out thick mucus and improve its outflow from the paranasal sinuses, and also help increase the duration of action of the drug.
Indications
- to facilitate nasal breathing during colds and viral infections of the upper respiratory tract, sinusitis, rhinitis of any etiology.
Contraindications
- atrophic rhinitis;
- children under 6 years of age;
- pregnancy;
- lactation period;
- hypersensitivity to the components of the drug.
The drug should be used with caution in patients with diseases of the cardiovascular system (arterial hypertension, coronary artery disease, chronic heart failure, tachycardia, arrhythmias), impaired carbohydrate metabolism (diabetes mellitus), impaired thyroid function (hyperthyroidism), pheochromocytoma, prostate hyperplasia with clinical symptoms, chronic renal failure, angle-closure glaucoma, with simultaneous use of MAO inhibitors, tricyclic antidepressants.
Use during pregnancy and breastfeeding
The drug is contraindicated during pregnancy and breastfeeding.
special instructions
It is not recommended to use Nazol Advance for more than 3 days.
Avoid contact of the drug with the eyes. The drug affects vision and may reduce reaction speed.
To avoid the spread of infection, it is necessary to use the drug individually.
Compound
Active substance: oxymetazoline hydrochloride 0.025 mg;
Excipients: benzalkonium chloride - 0.02 g; racemic camphor - 0.17 g; eucalyptol (cineole) - 0.17 g; levomenthol - 0.17 g; disodium edetate dihydrate - 0.1 g; polysorbate 80 - 0.2 g; propylene glycol - 10 g; sodium hydrogen phosphate dihydrate - 0.06 g; sodium dihydrogen phosphate dihydrate - 0.65 g; concentrated hydrochloric acid - 0.003 g; purified water - 89.711 g.
Directions for use and doses
Adults and children over 12 years old are prescribed 2-3 injections into each nasal passage 2 times a day, children aged 6 to 12 years (under adult supervision) - 1 injection into each nasal passage 2 times a day. The drug should not be used more than 2 times a day.
It is not recommended to use the drug for more than 3 days. With frequent or prolonged use of the drug, the feeling of difficulty in nasal breathing may reappear or worsen. If these symptoms appear, you should stop treatment and consult a doctor.
When spraying, do not tilt your head back and do not spray while lying down.
Side effects
Local reactions: sometimes a burning sensation or dryness of the nasal membranes, dryness in the mouth and pharynx, sneezing, an increase in the volume of secretions released from the nose. In rare cases, after the effect of using the drug wears off, a strong feeling of “stuffiness” in the nose (reactive hyperemia).
Systemic reactions: increased blood pressure, headache, dizziness, palpitations, increased anxiety, nausea, insomnia. With long-term use of the drug (more than 7 days), reactive hyperemia of the nasal mucosa and atrophy of the nasal mucosa are possible.
Drug interactions
When used simultaneously with MAO inhibitors and tricyclic antidepressants, an increase in blood pressure may be observed.
The drug slows down the absorption of local anesthetic drugs and prolongs their effect.
Co-administration of other vasoconstrictor drugs increases the risk of side effects.
Overdose
Symptoms: prolonged or frequent use of the drug in the nasal cavity can cause nausea, increased blood pressure, tachycardia, and central nervous system depression.
Treatment: carry out symptomatic therapy.
Storage conditions
The drug should be stored in a dry place, out of reach of children, at a temperature of 2° to 25°C.
Best before date
2 years.
MOMAT RINO ADVANCE spray 140 mcg+50 mcg/dose 150 doses
Below are special instructions for the active ingredients of the combination drug azelastine hydrochloride + mometasone furoate (nasal spray). Momat Rino Advance is recommended for use only in adults over 18 years of age.
Azelastine hydrochloride: There are no special instructions for the use of azelastine hydrochloride in the form of a nasal spray.
Mometasone furoate:
Immunosuppression: Mometasone furoate (nasal spray) should be used with caution or should not be used in patients with active or suspected tuberculous respiratory tract infection, or untreated fungal, bacterial, or systemic viral infections. Patients treated with corticosteroids have a potentially reduced immune responsiveness and should be advised of their increased risk of infection if exposed to patients with certain infectious diseases (eg, chickenpox, measles), and of the need for medical advice if such exposure occurs. happened.
Local nasal action: After 12 months of treatment with mometasone furoate (nasal spray) in a study in patients with chronic rhinitis, there were no signs of atrophy of the nasal mucosa, in addition, with treatment with mometasone furoate, there was a tendency for the nasal mucosa to return closer to the normal histological phenotype. However, patients using mometasone furoate nasal spray for several months or longer should be periodically monitored for possible changes in the nasal mucosa. If a localized fungal infection of the nasopharynx develops, it may be necessary to discontinue mometasone furoate (nasal spray) or prescribe appropriate treatment. An indication for discontinuation of mometasone furoate (nasal spray) may be a constantly present feeling of irritation of the nasopharynx.
Mometasone furoate (nasal spray) is not recommended for use in the presence of perforation of the nasal septum.
In clinical studies, nosebleeds occurred more frequently than with placebo. Nosebleeds were usually self-stopping and mild in severity.
Systemic effects of glucocorticosteroids: When using nasal glucocorticosteroids, systemic effects may occur, especially with long-term use of high doses of these drugs. These effects are much less likely to occur than with oral corticosteroids and may vary in individual patients and with different corticosteroids used. Potential systemic effects may include Cushing's syndrome, development of Cushingoid features, adrenal suppression, growth retardation in children and adolescents, cataracts, glaucoma, and much less commonly, a range of psychological or behavioral effects, including psychomotor hyperactivity, sleep disorders, anxiety, depression, or aggression (especially in children).
Cases of increased intraocular pressure have been described after the use of intranasal glucocorticosteroids.
During the transition from treatment with systemic corticosteroids to treatment with mometasone furoate (nasal spray), some patients may experience initial symptoms of systemic corticosteroid withdrawal (eg, joint and/or muscle pain, fatigue, and depression), despite a decrease in the severity of symptoms associated with systemic corticosteroids. with damage to the nasal mucosa; such patients must be specifically convinced of the advisability of continuing treatment with mometasone furoate (nasal spray). Switching from systemic to topical glucocorticosteroids may also reveal pre-existing allergic diseases such as allergic conjunctivitis and eczema that were masked by systemic glucocorticosteroid therapy.
Therapy with doses higher than recommended may cause clinically significant suppression of adrenal function. Therefore, during periods of stress or planned surgical interventions, when the need to use doses exceeding the recommended ones is obvious, the possibility of additional use of systemic glucocorticosteroids should be considered.
Nasal polyps: The safety and effectiveness of mometasone furoate nasal spray have not been studied in the treatment of unilateral polyps, cystic fibrosis polyps, or polyps causing complete obstruction of the nasal passages. The use of the drug for unilateral polyps that are characterized by an unusual or heterogeneous appearance, especially if they are accompanied by ulceration or bleeding, needs further study.
Non-nasal symptoms: Although intranasal mometasone furoate (nasal spray) provides control of nasal symptoms in most patients, the combined use of appropriate additional medications may reduce other symptoms, especially ophthalmic ones.
The drug Momat Rino Advance contains benzalkonium chloride, which can cause irritation of the nasal mucosa and bronchospasm.
Impact on the ability to drive vehicles and engage in other activities: In rare cases, fatigue, fatigue, dizziness and weakness, which may be a consequence of the disease itself, may develop when using Momat Rhino Advance nasal spray. In such cases, you should avoid driving a vehicle and working with complex mechanisms.
Nazol Advance
Nazol Advance (INN oxymetazoline) is a local vasoconstrictor for the symptomatic treatment of runny nose. Vasoconstrictors are the first choice drugs in the treatment of a runny nose. They interact with alpha-adrenergic receptors on the inner lining of the nasal cavity, reducing hyperemia, swelling and mucous secretion. Local vasoconstrictors (local vasoconstrictors) vary in the degree and duration of action, as well as in the severity of unwanted side reactions. Nazol Advance is considered one of the most “successful” vasoconstrictors in terms of effectiveness and safety. It eliminates the signs of rhinorrhea for 10-12 hours (for comparison: the duration of action of drugs based on xylometazoline is up to 8 hours) and does not cause addiction even with prolonged use, which is often the “sin” of naphazoline. It is important that oxymetazoline is absorbed into the systemic circulation to an extremely small extent, which minimizes the risk of developing systemic side effects. In addition to oxymetazoline, Nazol Advance contains natural ingredients: eucalyptus, camphor, menthol. They help eliminate inflammation and swelling, facilitate the evacuation of mucous secretions (due to stimulation of the drainage function of the ciliated epithelium), and have disinfecting properties. The glycols contained in the drug as excipients have a moisturizing effect, which prevents dehydration of the nasal mucosa and suppression of natural defense mechanisms. The drug is available in the form of a spray, which can also be regarded as an advantage: this form of release, unlike drops, ensures the distribution of the active substances throughout the entire inner lining of the nasal cavity without rolling into the nasopharynx. The effect of the drug appears 10-15 minutes after injection into the nasal passages. Single dose – 2-3 injections into each nostril (patients over 12 years old), 1 injection (patients from 6 to 12 years old). Frequency of application - no more than twice a day.
The maximum recommended duration of use is three days. If the recommended frequency and/or duration of use of the drug is exceeded, breathing through the nose may again become difficult. In such a situation, it is necessary to interrupt pharmacotherapy and seek medical advice to adjust treatment. When spraying the drug in the nasal passages, it is not recommended to lift your head and take a horizontal position. Nazol Advance has a favorable safety profile and is well tolerated. In rare cases, local undesirable side reactions are possible: irritating sensation of heat and/or dryness of the nasal mucosa, hyposalivation, sneezing, rhinorrhea. Sometimes, after the effect of the drug ends, reactive hyperemia may develop - a strong feeling of obstruction of the nasal passages. When using the drug in submaximal and maximum doses for a long time, systemic side effects may occur: transient arterial hypertension, cephalalgia, palpitations, vomiting, insomnia. The drug is not used for atrophy of the nasal mucosa and the nerve endings located in them, individual intolerance to the active or any of the auxiliary components of the drug, as well as during pregnancy and lactation. In pediatric practice, Nazol Advance is used starting from the age of six. There are a number of people who should be under medical supervision when using the drug: these are patients suffering from hypertension, coronary artery disease, decompensated myocardial dysfunction, people with rapid heartbeat, diabetes mellitus, hyperfunction of the thyroid gland, prostate adenoma, progressive kidney damage, accompanied by the death of the kidney. tissue, angle-closure glaucoma. To prevent the spread of bacterial infections, it is recommended not to share the drug for use with others.
